Skip to main content
Premium Trial:

Request an Annual Quote

Investing in DNA

When it comes to investing, sometimes thinking small is best, says Forbes' Yuval Bar-Or. Progress in technology and innovative products associated with DNA sequencing and the human genome could mean investment opportunities. As the $1,000 (or cheaper) genome approaches, the implications are "at once wondrous and disturbing," says Bar-Or, who hold investments in Illumina and Life Technologies. "Ongoing discoveries will usher in a new age of gene-based products and services. Savvy investors will undoubtedly reap rich rewards," he adds. Even considering the possible ethical and legal challenges that will ensue as technology becomes more and more advanced, it's doubtful that these problems will slow the growth of companies that manufacture the technology, Bar-Or says.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.